CIBC Private Wealth Group LLC Has $26.19 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

CIBC Private Wealth Group LLC reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 111,727 shares of the medical instruments supplier’s stock after selling 3,000 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Becton, Dickinson and Company were worth $26,192,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in Becton, Dickinson and Company by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier’s stock worth $6,067,196,000 after buying an additional 184,288 shares in the last quarter. State Street Corp boosted its position in shares of Becton, Dickinson and Company by 0.8% during the 3rd quarter. State Street Corp now owns 13,953,116 shares of the medical instruments supplier’s stock worth $3,364,096,000 after acquiring an additional 106,616 shares in the last quarter. Geode Capital Management LLC increased its stake in Becton, Dickinson and Company by 1.8% in the third quarter. Geode Capital Management LLC now owns 6,285,513 shares of the medical instruments supplier’s stock valued at $1,510,050,000 after acquiring an additional 111,101 shares during the last quarter. First Eagle Investment Management LLC raised its position in Becton, Dickinson and Company by 31.4% during the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier’s stock valued at $1,004,132,000 after purchasing an additional 1,057,879 shares in the last quarter. Finally, Norges Bank bought a new stake in Becton, Dickinson and Company during the fourth quarter worth $735,523,000. Institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Richard Byrd sold 1,940 shares of the firm’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the transaction, the executive vice president now owns 7,411 shares in the company, valued at approximately $1,666,808.01. This trade represents a 20.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bertram L. Scott sold 700 shares of the company’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total transaction of $159,593.00. Following the completion of the sale, the director now directly owns 36,033 shares in the company, valued at approximately $8,215,163.67. This represents a 1.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of research analyst reports. Barclays boosted their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Tuesday, March 25th. Finally, Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $278.29.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $229.37 on Tuesday. The firm has a market capitalization of $65.86 billion, a price-to-earnings ratio of 38.10, a PEG ratio of 1.63 and a beta of 0.35. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average price is $231.66 and its 200-day moving average price is $231.67. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its Board of Directors has approved a stock repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.81%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.